An experimental drug designed to control itching in people with moderate-to-severe AD shows promise in early trial.
Biologic Treatments for Moderate to Severe Atopic Dermatitis
A new study shows that mutations in the gene CARD11 are associated with severe atopic disease.
Patients with severe atopic dermatitis who have lower serum vitamin D levels have a high sensitivity to house dust mites which can aggravate their condition, a new study shows.
In early research, subcutaneous nemolizumab significantly reduced pruritus in moderate-to-severe atopic dermatitis adult patients.
Long-term data for dupilumab in atopic dermatitis revealed at the American Academy of Dermatology (AAD) 75th Annual Meeting reflect safety, rapid relief of troublesome symptoms and a long-lived response in keeping with the drug’s breakthrough status, experts told Dermatology Times.
A new research center makes a database of five million human pathology specimens and 22,000 living consented patients, all searchable by diagnoses, as well as cutting edge human analytic techniques available to anyone interested in carrying out translational skin disease research on human cells and tissues.
New data suggests positive safety and efficacy profile. Further studies need to assess long-term use.
Microbial colonization in the development of inflammatory conditions and immune-mediated conditions is a hot research topic, and new dermatologic therapies can potentially result from greater understanding of the role of microbial communities on the skin and in the gut.
Part of the management of contact dermatitis is identifying the offending agent through patch testing and eliminating contact with the offending agent.
UK-based Ziarco Pharma Ltd. recently announced positive phase 2a results for ZPL-389, a once daily oral histamine H4 receptor antagonist, for the treatment of moderate to severe atopic dermatitis.